Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.
Concomitant and bismuth quadruple regimens cleared ~90% of patients and outperformed triple therapy; sequential achieved ~84%. Adherence remained ~97% despite higher but manageable side effects.
"Prior exposure to TNF antagonists appears to potentiate the efficacy of JAK inhibitors and IL-12/23 antagonists but may attenuate responsiveness to lymphocyte trafficking inhibitors."